Some commentary from Macquarie emailed yesterday, this looks to be a major issue ATM and keeping the share price well below the 4.77 high.
Emerging Leaders
Acrux ACR Underperform
Rebates remain stubbornly high
* Eli Lilly reported Axiron 4Q net sales at US$23.9m (vs. Macq at US$22.6m).
* Solid net sales number due to lower than expected rebate; however, it appears that the rebate has increased on a seasonally adjusted basis.
* Underperform. Positive that Q4 rebates were lower than Q3, but still increased on a seasonally adjusted basis and concern about slowing market growth.
rebate
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 152642 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 04/09/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable